240 related articles for article (PubMed ID: 7688103)
1. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice.
Entani C; Izumino K; Iida H; Fujita M; Asaka M; Takata M; Sasayama S
Nephron; 1993; 64(3):471-5. PubMed ID: 7688103
[TBL] [Abstract][Full Text] [Related]
2. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice.
Furukawa F; Imamura S; Takigawa M
Arch Dermatol Res; 1995; 287(6):558-63. PubMed ID: 7487142
[TBL] [Abstract][Full Text] [Related]
3. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.
Sugahara K; Maeda Y; Shimano K; Murase M; Mochiduki S; Takemoto K; Kakimoto T; Utsumi H; Oshita K; Kataoka H
J Immunol Res; 2019; 2019():5821589. PubMed ID: 31930150
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus Protects Podocytes from Injury in Lupus Nephritis Partly by Stabilizing the Cytoskeleton and Inhibiting Podocyte Apoptosis.
Liao R; Liu Q; Zheng Z; Fan J; Peng W; Kong Q; He H; Yang S; Chen W; Tang X; Yu X
PLoS One; 2015; 10(7):e0132724. PubMed ID: 26161538
[TBL] [Abstract][Full Text] [Related]
5. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
Pérez de Lema G; Lucio-Cazaña FJ; Molina A; Luckow B; Schmid H; de Wit C; Moreno-Manzano V; Banas B; Mampaso F; Schlöndorff D
Kidney Int; 2004 Sep; 66(3):1018-28. PubMed ID: 15327395
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of 15-deoxyspergualin on the progression of lupus nephritis in MRL mice. I. Immunopathological analyses.
Ito S; Ueno M; Arakawa M; Saito T; Aoyagi T; Fujiwara M
Clin Exp Immunol; 1990 Sep; 81(3):446-53. PubMed ID: 2397613
[TBL] [Abstract][Full Text] [Related]
7. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
Shi Y; Yao W; Sun L; Li G; Liu H; Ding P; Hu W; Xu H
BMC Nephrol; 2019 Nov; 20(1):424. PubMed ID: 31752725
[TBL] [Abstract][Full Text] [Related]
8. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
9. IL-3 contributes to development of lupus nephritis in MRL/lpr mice.
Renner K; Hermann FJ; Schmidbauer K; Talke Y; Rodriguez Gomez M; Schiechl G; Schlossmann J; Brühl H; Anders HJ; Mack M
Kidney Int; 2015 Nov; 88(5):1088-98. PubMed ID: 26131743
[TBL] [Abstract][Full Text] [Related]
10. Procyanidin B2 prevents lupus nephritis development in mice by inhibiting NLRP3 inflammasome activation.
He J; Sun M; Tian S
Innate Immun; 2018 Jul; 24(5):307-315. PubMed ID: 29874961
[TBL] [Abstract][Full Text] [Related]
11. (5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL/
Zhang LY; Li H; Wu YW; Cheng L; Yan YX; Yang XQ; Zhu FH; He SJ; Tang W; Zuo JP
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F769-F777. PubMed ID: 28100505
[TBL] [Abstract][Full Text] [Related]
12. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
[TBL] [Abstract][Full Text] [Related]
13. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506.
Yamamoto K; Mori A; Nakahama T; Ito M; Okudaira H; Miyamoto T
Immunology; 1990 Feb; 69(2):222-7. PubMed ID: 1689694
[TBL] [Abstract][Full Text] [Related]
14. Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in Murine Lupus Nephritis.
Gonzalo-Gil E; García-Herrero C; Toldos O; Usategui A; Criado G; Pérez-Yagüe S; Barber DF; Pablos JL; Galindo M
Front Immunol; 2018; 9():1948. PubMed ID: 30210500
[No Abstract] [Full Text] [Related]
15. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
Elliott MK; Jarmi T; Ruiz P; Xu Y; Holers VM; Gilkeson GS
Kidney Int; 2004 Jan; 65(1):129-38. PubMed ID: 14675043
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin Treatment Ameliorates Lupus Nephritis of MRL/lpr Mice.
Zhang Z; Liu D; Zhang X; Wang X
Inflammation; 2018 Oct; 41(5):1888-1899. PubMed ID: 29951872
[TBL] [Abstract][Full Text] [Related]
17. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
Jiang C; Zhao ML; Scearce RM; Diaz M
Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
[TBL] [Abstract][Full Text] [Related]
18. Intermittent Fasting Aggravates Lupus Nephritis through Increasing Survival and Autophagy of Antibody Secreting Cells in MRL/lpr Mice.
Hong SM; Lee J; Jang SG; Song Y; Kim M; Lee J; Cho ML; Kwok SK; Park SH
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187196
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
Sadanaga A; Nakashima H; Masutani K; Miyake K; Shimizu S; Igawa T; Sugiyama N; Niiro H; Hirakata H; Harada M
Arthritis Rheum; 2005 Dec; 52(12):3987-96. PubMed ID: 16320345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
